Speaker :

Dr. Chintan Shah, Medical Oncologist, Ahemdabad

Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor  2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results

Author: Hope S. Rugo

 Citation: Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1006-1006

Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib

Author: Felipe Batalini

 Citation: JCO Precision Oncology no. 4 (2020) 572-578